Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
lupus nephritis
Pharma
Roche's Gazyva succeeds in key lupus nephritis trial
Roche has shown results of a phase 3 trial which set up Gazyva for potential approval in what would be its most important indication—lupus nephritis.
Kevin Dunleavy
Feb 7, 2025 11:14am
Roche's Gazyva chases new kidney disease use with phase 3 win
Sep 26, 2024 11:30am
Aurinia brings singer Toni Braxton to Lupus Awareness Month push
May 1, 2024 9:15am
Aurinia quells investor unrest, names former CEO Foster to board
Sep 21, 2023 10:55am
GSK taps social media influencers to reach lupus community
Jul 21, 2023 4:00am
Novartis targets new fields—and CAR-T—for immunology growth
May 10, 2023 5:00pm
